Tonny
Super Bowl is over time to get back to work!
BLPH put it on your Radar!
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery device. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company intends to commence Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), which is in Phase 2 development and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF). The Company’s plans also call for the completion of further work on the use of INOpulse to treat PH-COPD and PH-IPF during 2016. For more information, please visit www.bellerophon.com.
Headlines
- 8:04 am Bellerophon Therapeutics announces data from the final analysis of the co's Phase 2 long-term extension study of INOpulse; believes it directly supports its design of Phase 3 studyBriefing.com(Tue 8:04AM EST)
- Bellerophon Therapeutics Announces Positive Data From the Final Analysis of the Phase 2 Long-Term Extension Study of INOpulse for Treatment of Pulmonary Arterial HypertensionGlobeNewswire(Tue 8:03AM EST)
- Bellerophon to Participate in LEERINK Partners 5th Annual Global Healthcare ConferenceGlobeNewswire(Wed, Feb 3)
- Bellerophon Therapeutics Announces Notice of Intention to Grant a European Patent Supporting Its INOpulse ProgramGlobeNewswire(Thu, Jan 21)
- Bellerophon Therapeutics Receives EC Certification for New INOpulse® Drug-Device Delivery SystemGlobeNewswire(Tue, Jan 19)
- MicroCap Review Magazine Winter/Spring 2016 Issue Now AvailableMarketwired(Tue, Jan 19)
- BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements aEDGAR Online(Tue, Jan 12)
- The Best and Worst IPO's of 2015at Motley Fool(Sun, Dec 13)
- BELLEROPHON THERAPEUTICS, INC. FinancialsEDGAR Online Financials(Tue, Dec 8)
Never invest in a stock mentioned by StockPalooza.com.com unless you can afford to lose your entire investment.
Release of Liability: Through use of this website viewing or using you agree to holdStockPalooza.com.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may suffer. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Please be advised that StockPalooza.com.com is often compensated for issuing press releases, profiles or opinions concerning particular companies, its opinion is therefore biased and you should consider the factor when evaluating StockPalooza.com.com's statements regarding a company. StockPalooza.com.com's officers and directors do not own any shares of the mentioned company(s). When StockPalooza.com.com receives free or restric ted trading shares as a compensation for a profiled company, StockPalooza.com .com may sell part or all of such shares during the period in which StockPalooza.com.com is performing such services. StockPalooza.com.com will disclose how many and what type of shares we have been compensated if we do receive shares or buy shares of a profiled company.StockPalooza.com.com has been compensated zero Cash via Bank Wire Transfer by a third party for a 1 day Marketing Program regarding BLPH. This compensation/expected compensation, expired or not, is a major conflict of interest in our ability to be unbiased. Therefore, this newsletter should be read as a commercial advertisement only. The third party, company, or their affiliates may wish to liquidate shares, which has the potential to hurt share prices . Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the t imeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. StockPalooza.com.comencourages readers and investors to supplement the information in this report with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockPalooza.com.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. StockPalooza.com.com, nor any of its affiliates are not registered investment. Stockpalooza's emails and alerts are intended for novelty purposes only.
11020 Vanowen St No. Hollywood CA 91605
|
|
|
|
